Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 20/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 20/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 20/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 0.68 |
| ▸ | MAOB | P27338 | 3/20 | 0.68 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29598740 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| Biphenyline SCHEMBL29519295 | 0.82 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL17722365 | 0.77 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL5827514 | 0.74 | ADRA2A (0.57) | ADRA2AADRA2BADRA2C | |
| SCHEMBL10041781 | 0.73 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL3787713 | 0.71 | AKR1C3 (0.60) | ADRA2AADRA2BADRA2C | |
| SCHEMBL17887785 | 0.71 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL12643294 | 0.70 | NISCH (0.58) | ADRA2AADRA2BADRA2CMAOBNISCH | |
| SCHEMBL29755942 | 0.70 | NISCH (0.58) | ADRA2AADRA2BADRA2CMAOBNISCH | |
| Hydrochloric Acid SCHEMBL2491030 | 0.69 | NISCH (0.56) | ADRA2AADRA2BADRA2CMAOBNISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-12 | — | — | US | claimed |
| WO-2023178183-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND ALPHA-2 ADRENERGIC RECEPTORS FOR TREATMENT OF STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-09-21 | — | — | WO | claimed |
| EP-4232013-A2 | OPIOID-FREE COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS AND RELATED METHODS AND SYSTEMS | Vaporworks Nursing Anesthesia Inc. (US) | 2023-08-30 | — | — | EP | claimed |
| US-20230165836-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER | Université Catholique de Louvain (BE) | 2023-06-01 | — | — | US | claimed |
| US-20230149360-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE PREVENTION AND/OR THE TREATMENT OF SPLEEN DISORDERS | Université Catholique de Louvain (BE) | 2023-05-18 | — | — | US | claimed |
| US-20230091848-A1 | DISEASE DETECTION AND TREATMENT BASED ON PHENYLACETYL GLUTAMINE LEVELS | THE CLEVELAND CLINIC FOUNDATION | 2023-03-23 | — | — | US | claimed |
| EP-4138802-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE PREVENTION AND/OR THE TREATMENT OF SPLEEN DISORDERS | Université catholique de Louvain (BE) | 2023-03-01 | — | — | EP | claimed |
| EP-4138803-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER | Université catholique de Louvain (BE) | 2023-03-01 | — | — | EP | claimed |
| EP-4100541-A1 | DISEASE DETECTION AND TREATMENT BASED ON PHENYLACETYL GLUTAMINE LEVELS | The Cleveland Clinic Foundation (US) | 2022-12-14 | — | — | EP | claimed |
| US-20220218740-A1 | OPIOID-FREE COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS AND RELATED METHODS AND SYSTEMS | VAPORWORKS NURSING ANESTHESIA INC. | 2022-07-14 | — | — | US | claimed |
| WO-2021214175-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE PREVENTION AND/OR THE TREATMENT OF SPLEEN DISORDERS | Université Catholique de Louvain (BE) | 2021-10-28 | — | — | WO | claimed |
| WO-2021158720-A1 | DISEASE DETECTION AND TREATMENT BASED ON PHENYLACETYL GLUTAMINE LEVELS | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-08-12 | — | — | WO | claimed |
| US-10632105-B2 | Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord motor disorders | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2020-04-28 | — | — | US | claimed |
| US-20180280693-A1 | CONCERTED USE OF NONINVASIVE NEUROMODULATION DEVICE WITH EXOSKELETON TO ENABLE VOLUNTARY MOVEMENT AND GREATER MUSCLE ACTIVATION WHEN STEPPING IN A CHRONICALLY PARALYZED SUBJECT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-10-04 | — | — | US | claimed |
| WO-2017035512-A1 | CONCERTED USE OF NONINVASIVE NEUROMODULATION DEVICE WITH EXOSKELETON TO ENABLE VOLUNTARY MOVEMENT AND GREATER MUSCLE ACTIVATION WHEN STEPPING IN A CHRONICALLY PARALYZED SUBJECT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-02 | — | — | WO | claimed |
| US-20160158204-A1 | PHARMACOLOGICAL STIMULATION TO FACILITATE AND RESTORE STANDING AND WALKING FUNCTIONS IN SPINAL CORD MOTOR DISORDERS | ONWARD MEDICAL N.V. (NL) | 2016-06-09 | — | — | US | claimed |
| WO-2015000800-A1 | PHARMACOLOGICAL STIMULATION TO FACILITATE AND RESTORE STANDING AND WALKING FUNCTIONS IN SPINAL CORD MOTOR DISORDERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2015-01-08 | — | — | WO | claimed |
| EP-2731606-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | Allergan, Inc. (US) | 2014-05-21 | — | — | EP | claimed |
| US-20130079379-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | ALLERGAN, INC. (US) | 2013-03-28 | — | — | US | claimed |
| WO-2013010032-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | ALLERGAN, INC. (US) | 2013-01-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079379-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | CUTA, PDE3A, PTGIS | ADRA2A 170/4885ADRA2B 1086/4885ADRA2C 684/4885 |
| US-10632105-B2 | Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord motor disorders | ADRA2C, ADRA2A, ADRB2 | ADRA2A 2/4885ADRA2B 6/4885ADRA2C 1/4885 |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | GABRB2, GABRB1, ADRB2 | ADRA2A 7/4885ADRA2B 5/4885ADRA2C 8/4885 |
| US-20160158204-A1 | PHARMACOLOGICAL STIMULATION TO FACILITATE AND RESTORE STANDING AND WALKING FUNCTIONS IN SPINAL CORD MOTOR DISORDERS | ADRA2C, ADRA2A, ADRB2 | ADRA2A 2/4885ADRA2B 6/4885ADRA2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.